scholarly journals Optimizing Physician Payment Models to Address Health System Priorities: Perspectives from Specialist Physicians

2021 ◽  
Vol 17 (1) ◽  
pp. 58-72
Author(s):  
Yewande Ogundeji ◽  
Amity Quinn ◽  
Meaghan Lunney ◽  
Christy Chong ◽  
Derek Chew ◽  
...  
2018 ◽  
Vol 79 (1) ◽  
pp. 175-177
Author(s):  
Oluwatobi A. Ogbechie-Godec ◽  
Arash Mostaghimi ◽  
Vinod E. Nambudiri

2021 ◽  
Vol 31 (Supplement_3) ◽  
Author(s):  
◽  

Abstract   To keep health care sustainable while ensuring that patients receive the best possible care, there is a need to find suitable ways of organising and structuring health care that are better applicable to for example the treatment of non-communicable diseases and multimorbidity. Improving coordination processes across different health and social care actors is crucial and as pressures on health systems have mounted, there has been increasing interest in how different methods of delivering or paying for healthcare can help in achieving overall health system goals. Some countries have set up specific ‘Innovation funds' to support the testing of new care and payment models. In this workshop we will have a closer look at how such dedicated funding programmes can be used as a tool to foster this particular type of innovation. This is especially valuable for participants who are interested in the initial or further development of such funding streams. The workshop will have the format of a regular workshop and will start with four presentations followed by ample time for an interactive discussion on specific subtopics or questions raised by the audience. Key messages This workshop will allow for cross country learning and evaluation of funding programmes that invest in new care and payment models and create opportunities for shared learning and collaboration. This workshop will also draw more attention towards current developments on how new care and payment models can be developed, invested in and implemented.


2021 ◽  
Author(s):  
Sarah Raes ◽  
Jeroen Trybou ◽  
Lieven Annemans

BACKGROUND Many researchers have addressed the lack of reimbursement for telemedicine as one of the most important barriers to telemedicine adoption. However, little is known on how telemedicine should be implemented in reimbursement policy, how it must be financed, and what the right incentives are for an effective and efficient telemedicine use. OBJECTIVE To help future researchers to provide reimbursement policy recommendations, and to facilitate reimbursement decision-making, this paper analyzed and compared the telemedicine payment models of ten countries. METHODS A convenience sample was created of Western countries inside and outside Europe that already reimburse to some extent telemedicine. Ten countries met this criterion: Australia, Belgium, Denmark, France, Germany, Luxembourg, the Netherlands, Canada (Ontario province), Switzerland, and the United Kingdom. The study was based on the countries’ official physician fee schedules, listing all reimbursed medical services performed by physicians, including telemedicine. Based on the fee schedules, a comparative analysis of the payment models of telemedicine was conducted. RESULTS Televisits are reimbursed in all countries, which is not the case for telemonitoring and tele-expertise services. Telemonitoring is often restricted for patients with implanted cardiac devices. Telemedicine services are mainly paid fee-for-service, except for the telemonitoring of patients with implanted cardiac devices, which is paid through an episodic payment system in Australia. Payment parity exists across televisits and visits in person in France, Luxembourg, the Netherlands, and Switzerland, meaning that an equal fee is given for both services. CONCLUSIONS Our findings show that fees for telemedicine are lacking, especially for telemonitoring and tele-expertise. As telemedicine might enlarge disparities in healthcare access, policymakers should consider payment parity across televisits and face-to-face visits, and across telephone and video visits. Furthermore, an episodic physician payment system complemented with bonuses for quality outcomes, should be considered by policymakers for telemonitoring as it might capture the specificities of telemonitoring better than a fee-for-service system. Future research is needed on payment models, including research linking cost-effectiveness analyses with analyses on payment models, to allow profound reimbursement recommendations and a faster decision-making process for the reimbursement of telemedicine.


2020 ◽  
Vol 156 (3) ◽  
pp. 701-709
Author(s):  
Margaret I. Liang ◽  
Emeline M. Aviki ◽  
Jason D. Wright ◽  
Laura J. Havrilesky ◽  
Leslie R. Boyd ◽  
...  

2014 ◽  
Vol 151 (1_suppl) ◽  
pp. P8-P8
Author(s):  
Jane T. Dillon ◽  
Richard W. Waguespack ◽  
Emily F. Boss ◽  
Robert R. Lorenz ◽  
Randal S. Weber

2011 ◽  
Vol 7 (2) ◽  
pp. 197-226 ◽  
Author(s):  
Dominika Wranik

AbstractThis paper assesses which policy-relevant characteristics of a healthcare system contribute to health-system efficiency. Health-system efficiency is measured using the stochastic frontier approach. Characteristics of the health system are included as determinants of efficiency. Data from 21 OECD countries from 1970 to 2008 are analysed. Results indicate that broader health-system structures, such as Beveridgian or Bismarckian financing arrangements or gatekeeping, are not significant determinants of efficiency. Significant contributors to efficiency are policy instruments that directly target patient behaviours, such as insurance coverage and cost sharing, and those that directly target physician behaviours, such as physician payment methods. From the perspective of the policymaker, changes in cost-sharing arrangements or physician remuneration are politically easier to implement than changes to the foundational financing structure of the system.


Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Jason Shafrin ◽  
Elmar R Aliyev ◽  
Michelle Brauer ◽  
Siyeon Park ◽  
Xian Shen

Introduction: The PIONEER-HF trial demonstrated superior efficacy of sacubitril/valsartan over the angiotensin-converting-enzyme inhibitor (ACEi) enalapril in treating patients with acute decompensated heart failure (ADHF) after stabilization in the inpatient setting, but how medication choice affects health system finances is unknown. Measuring the financial impact is complicated as health systems are increasingly reimbursed through value-based alternative payment models (APM). Methods: A decision tree model was used to assess the financial impact of health system adoption of sacubitril/valsartan to treat ADHF under APM reimbursement. The model estimated differences in health care utilization and cost when treating hospitalized ADHF patients with ACEi or angiotensin-receptor blockers compared to sacubitril/valsartan using efficacy results from PIONEER-HF. The financial impact on health systems was assessed across three common APMs: Medicare Shared Savings Program (MSSP), Bundled Payments for Care Improvement (BPCI), and fee-for-service payments adjusted via the Hospital Readmission Reduction Program (HRRP). Results: Sacubitril/valsartan reduced re-hospitalizations after an ADHF admission by 46.3% for individuals aged 18-64 years and 23.4% for individuals aged ≥65 years. Health system financial benefit from adopting sacubitril/valsartan was $740 per ADHF case per year (PCPY). Savings were larger for patients aged ≥65 years ($803 PCPY) compared to those <65 years ($653 PCPY). Adoption of sacubitril/valsartan improved health system finances under value-based APMs with the largest financial benefits under the HRRP ($1,190 financial gain PCPY), followed by BPCI ($645 financial gain PCPY) and MSSP ($253 financial gain PCPY). Conclusions: Adoption of sacubitril/valsartan to treat ADHF is expected to decrease hospitalizations and lead to a positive net financial impact on health systems under the commonly implemented APMs.


Sign in / Sign up

Export Citation Format

Share Document